VIDEO: Inebilizumab effective in preventing relapses in neuromyelitis optica

SEATTLE – Inebilizumab was shown to be safe and effective in preventing relapses in individuals with neuromyelitis optica spectrum disorder, a speaker said at the 2022 American Academy of Neurology annual meeting.

Bruce Cree, MD, PhD, professor of neurology at the University of California, San Francisco, said the study also showed that inebilizumab is effective at preventing clinical attacks, worsening disability, new lesions from forming on MRI and hospitalizations.